Clinical Trial Search

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Repaglinide (Cohort 1) — 13.0; 13.6 nanogram*hour per…

Primary: Knee Flexion Moment Impulse — 0.54; 0.50 Ratio — p=0.293

Primary: Intervention Feasibility: Enrollment Rates Among Eligible Patients Screened — 67; 60; 27; 37 Participants

Primary: Localizing Brain Regions That Generate Interictal Spikes — 52 Participants

Primary: Change From Baseline in the Overall Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive…

Primary: Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5α-cholanic Acid-3β, 5α, 6β-triol N-(Carboxymethyl)-Amide — 32.6; 87.9 ng/ml

Primary: Body Mass Index (BMI) Change — 1.51; 0.91 kg/m^2

Primary: Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) — 0.032; 0.023 logMAR

Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale

Primary: Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52 — 32.2; 50.3 Percentage of participants

Primary: Number of Participants According to Geographic Region — 240; 94; 93; 80 Participants

Primary: Six Minute Walk Test - First Paired Sessions — 413; 387 Feet — p=0.2795

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1) — 1810; 4350 nanogram*hour per milliliter…

Primary: Cohort A: Gait Speed Measured by APDM, GAITRite Walkway and ActiGraph Devices for Walk at Natural, Slow and Fast Speed Tasks — 0.83; 1.00; 1.04; 0.93 Meters per second

Primary: Total Opioid Use — 0.0; 0.0 mg